ALIMP Stock Overview
Implanet S.A., a medical technology company, manufactures and sells implants for orthopedic surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Implanet S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.071 |
| 52 Week High | €0.21 |
| 52 Week Low | €0.035 |
| Beta | 1.23 |
| 1 Month Change | 1.43% |
| 3 Month Change | 10.94% |
| 1 Year Change | -64.85% |
| 3 Year Change | -93.13% |
| 5 Year Change | -98.52% |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| ALIMP | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -0.3% | 0.7% | 2.2% |
| 1Y | -64.9% | 10.2% | 3.2% |
Return vs Industry: ALIMP underperformed the French Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: ALIMP underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| ALIMP volatility | |
|---|---|
| ALIMP Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALIMP has not had significant price volatility in the past 3 months.
Volatility Over Time: ALIMP's weekly volatility has decreased from 24% to 12% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 41 | Ludovic Lastennet | www.implanet.com |
Implanet S.A., a medical technology company, manufactures and sells implants for orthopedic surgery. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation.
Implanet S.A. Fundamentals Summary
| ALIMP fundamental statistics | |
|---|---|
| Market cap | €8.87m |
| Earnings (TTM) | -€6.68m |
| Revenue (TTM) | €7.45m |
1.2x
P/S Ratio-1.3x
P/E RatioIs ALIMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIMP income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €4.12m |
| Gross Profit | €3.33m |
| Other Expenses | €10.00m |
| Earnings | -€6.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 10, 2024
| Earnings per share (EPS) | -0.053 |
| Gross Margin | 44.65% |
| Net Profit Margin | -89.65% |
| Debt/Equity Ratio | -3,174.7% |
How did ALIMP perform over the long term?
See historical performance and comparison